Intramuscular immunization with a DNA vaccine encoding a 26-amino acid CETP epitope displayed by HBc protein and containing CpG DNA inhibits atherosclerosis in a rabbit model of atherosclerosis

Vaccine

Volumn 24, Issue 23, 2006, Pages 4942-4950

  Mao, Dan ^a   Kai, Gu ^a   Gaofu, Qi ^a   Zheng, Zhu ^a   Li, Zhong ^a   Jie, Wu ^a   Jingjing, Liu ^a   Rongyue, Cao ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis; Cholesteryl ester transfer protein; CpG; DNA immunization; Immunostimulatory sequence; Vaccine

Indexed keywords

AMINO ACID DERIVATIVE; ARGINYLASPARTYLGLYCYLPHENYLALANYLLEUCYLLEUCYLLEUCYLGLUTAMINYLMETHIONYL ASPARTYLPHENYLALANYLGLYCYLPHENYLALANYLPROLYLGLUTAMYLHISTIDYLLEUCYLLEUCYLVALYL ASPARTYLPHENYLALANYLLEUCYLGLUTAMINYLSERYLLEUCYLSERINE; CHOLESTEROL ESTER TRANSFER PROTEIN; CPG OLIGODEOXYNUCLEOTIDE; DNA FRAGMENT; DNA VACCINE; EPITOPE; HEPATITIS B CORE ANTIGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOMODULATING AGENT; ISCOM; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMID DNA; PROTEIN ANTIBODY; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROGENESIS; CARBOXY TERMINAL SEQUENCE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; CORONARY ARTERY; DISEASE COURSE; DNA CONTENT; DNA SEQUENCE; DNA VECTOR; DRUG EFFECT; DRUG SCREENING; FEEDING; GENETIC CODE; HYPERPLASIA; IMMUNIZATION; LIPID ANALYSIS; MONKEY; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; RABBIT; THICKNESS; VACCINATION; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE;

ANIMALS; ANTIBODIES; AORTA; ATHEROSCLEROSIS; CARRIER PROTEINS; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; CORONARY VESSELS; CPG ISLANDS; EPITOPES; GENETIC VECTORS; GLYCOPROTEINS; HEPATITIS B CORE ANTIGENS; INJECTIONS, INTRAMUSCULAR; KIDNEY; LIPOPROTEINS; RABBITS; VACCINES, DNA;

EID: 33646884783     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.03.082     Document Type: Article

References (23)

1. Sherer Y., and Shoenfeld Y. Atherosclerosis. Ann Rheum Dis 61 (2002) 97-99
2. Durrington P. HDL in risk prediction and its direct and indirect involvement in atherogenesis. Atherosclerosis Suppl (2002) 3-12
3. Barter P.J. CETP and atherosclerosis. Arterioscler Thromb Vase Biol 20 (2000) 2029-2031
4. Yamashita S., Hirano K., Sakai N., and Matsuzawa Y. Molecular biology and pathophysilogical aspects of plasma cholesteryl ester transfer protein. Biochimica et Biophysica Acta 1529 (2000) 257-275
5. Parini P., and Rudel L.L. Is there a need for cholesteryl ester transfer protein inhibition?. Arterioscler Thromb Vase Biol 23 (2003) 374-375
6. Barter P.J., et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vase Biol 23 (2002) 160-167
7. Rittershaus C.W., et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vase Biol 20 (2000) 2106-2112
8. Davidson M.H., et al. The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis 169 (2003) 113-120
9. Wang S., Deng L., Milne R.W., and Tall A.R. Identification of a sequence within the C-terminal 26 amino acids of cholesteryl ester transfer protein responsible for binding a neutralizing monoclonal antibody and necessary for neutral lipid transfer activity. J Biol Chem 267 (1992) 17487-17490
10. Qi G., Mao D., Wu J., et al. Long-lasting specific antibodies against CETP induced by subcutanesous and mucosal administration of a 26-amino acid CETP epitope carried by heat shock protein 65 kDa in the absence of adjuvants. Vaccine 22 (2004) 3187-3194
11. Qi G., Long J., Yang X., et al. Vaccinating rabbits with a cholesteryl ester transfer protein(CETP) B-cell epitope carried by heat shock protein-65 (HSP65) for inducing anti-CETP antibodies and reducing aortic lesions in vivo. J Cardiovasc Pharmacol 45 (2005) 591-598
12. Sherer Y., and Shoenfeld Y. Immunomodulation for treatment and prevention of atherosclerosis. Autoimmun Rev 1 (2002) 21-27
13. Hansson G.K. Vaccination against atherosclerosis: Science or fiction?. Circulation 106 (2002) 1599-1601
14. Hasan U.A., et al. Nucleic acid immunization: concepts and techniques associated with third generation vaccines. J Immunol Methods 229 1-2 (1999) 1-22
15. Krieg A.M. Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta 1489 1 (1999) 107-116
16. Klinman D.M., Barnhart K.M., and Conover J. CpG motifs as immune adjuvants. Vaccine 17 (1999) 19-25
17. Boccaccio G.L., Mor F., and Steinman L. Non-coding plasmid DNA induces IFN-γ in vivo and suppresses autoimmune encephalomyelitis. Int Immunol 11 (1999) 289-296
18. Quintana F.J., Rotem A., Carmi P., and Cohen I.R. Vaccination with empty plasmid DNA or CpG oligonucleotide inhibits diabetes in nonobese diabetic mice: modulation of spontaneous 60-kDa heat shock protein autoimmunity. J Immunol 165 (2000) 6148-6155
19. Wick G., Knoflach M., and Xu Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol 22 (2004) 361-403
20. Pumpens P., Borisova G.P., Crowther R.A., and Grens E. Hepatitis B virus core particles as epitope carriers. Intervirology 38 (1995) 63-74
21. Bottcher B., Wynne S.A., and Crowther R.A. Determination of the fold of the core protein of hepatitis B virus by electron cryomicroscopy. Nature 386 6620 (1997) 88-91
22. Jingjing L., Xue Y., Agarwal N., and Roque R.S. Human Muller cells express VEGF183, a novel spliced variant of vascular endothelial growth factor. Invest Ophthalmol Vis Sci 40 (1999) 752-759
23. Verthelyi D., and Kilnman D. Imunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clin Immunol 109 (2003) 64-71